Observational studyOphthalmology2020
Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8.
Observational study in Ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Clinical characteristics, imaging features, and treatment outcomes of macular telangiectasia type 2: a comprehensive meta-analysis.Scientific reports · 2026Pooled it
- Optical coherence tomography angiography measurements in tamoxifen associated retinopathy: a systematic review and meta-analysis.BMC ophthalmology · 2025Pooled it
- Functional Relevance of Hyper-Reflectivity in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2021Trial
- Macular Holes Secondary to Macular Telangiectasia Type 2: Pathogenesis, Clinical Features, Imaging and Surgical Management.Journal of clinical medicine · 2026Review
- Prevalence and Visual Acuity Characteristics of Patients with Macular Telangiectasia.Ophthalmology and therapy · 2026Article
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Longitudinal spatial correlation of retinal sensitivity and structural changes in macular telangiectasia type 2.International journal of retina and vitreous · 2026Article
- Optical Coherence Tomography Angiography Characterization of Vascular Alterations in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2026Observational
- Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2.Ophthalmology science · 2026Article
- Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025Review
- Retinal pigment epithelial cells reduce vascular leak and proliferation in retinal neovessels.Angiogenesis · 2024Article
- Quantification of vascular changes in macular telangiectasia type 2 with AngioTool software.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Right-angled vessel characteristics in different stages of type 2 macular telangiectasia (MacTel).Eye (London, England) · 2024Article
- Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.International journal of retina and vitreous · 2023Review
- Longitudinal anatomical and visual outcome of macular telangiectasia type 2 in Asian patients.Scientific reports · 2023Article
- Macular Telangiectasia Type 2: A Classification System Using MultiModal Imaging MacTel Project Report Number 10.Ophthalmology science · 2023Article
- Structural-vascular-functional correlation in type 2 non-proliferative macular telangiectasia.International journal of retina and vitreous · 2022Article
- Distribution of macular pigments in macular telangiectasia type 2 and correlation with optical coherence tomography characteristics and visual acuity.BMC ophthalmology · 2022Article
- Imaging endpoints for clinical trials in MacTel type 2.Eye (London, England) · 2022Review
- Commentary: Imaging in macular telangiectasia type 2 - Correlating structural change with vision.Indian journal of ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeTo report the visual acuity measures from the macular telangiectasia type 2 (MacTel) registry and to investigate and describe phenotypic findings in eyes with substantial vision loss resulting from MacTel.
designCross-sectional multicenter study.
participantsParticipants in the MacTel Natural History Observation Registration Study.
methodsBest-corrected visual acuity (BCVA) data, retinal imaging data, and clinical data were accessed from the MacTel Study databases in May 2019.
main outcome measuresFrequency distribution of BCVA and its relationship to age; morphologic changes in eyes with very late disease stages, defined by a BCVA of 20/200 or worse; average retinal thickness of macular subfields on OCT; and dimensions of the area affected by MacTel (i.e., the MacTel area).
resultsBest-corrected visual acuity was 20/50 or worse in 37.3% and 20/200 or worse in 3.8% of 4449 eyes of 2248 patients; 18.4% and 0.7% of all patients showed bilateral BCVA of 20/50 or worse and 20/200 or worse, respectively. Asymmetry between right and left eyes was present (median BCVA, 71 letters vs. 74 letters), a finding supported by more advanced morphologic changes in right eyes. Participant age correlated with BCVA, but the effect size was small. If a neovascularization or macular hole were present, bilateral occurrence was frequent (33% or 17%, respectively), and BCVA was better than 20/200 (79% or 78%, respectively) or 20/50 or better (26% or 13%, respectively). Eyes with advanced disease (BCVA, ≤20/200) showed the following characteristics: (1) atrophy of the foveal photoreceptor layer with or without associated subretinal fibrosis; (2) an affected area, termed MacTel area, limited to a horizontal diameter not exceeding the distance between the temporal optic disc margin and foveal center, and the vertical diameter not exceeding approximately 0.8 times this distance (exceptions were eyes with large active or inactive neovascular membranes); (3) reduced retinal thickness measures within the MacTel area; and (4) less frequent retinal greying and more frequent hyperpigmentations compared with eyes that have better BCVA.
conclusionsSevere vision loss is rare in MacTel and is related to photoreceptor atrophy in most people. Results indicate disease asymmetry with slightly worse vision and more advanced disease manifestation in right eyes. MacTel-related neurodegeneration does not spread beyond the limits of the MacTel area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.